SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 424B5
Document Type: 424B5
Date Filed: 2025-12-09
Accession Number: 0001213900-25-119671
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025119671/ea0268926-424b5_synergy.htm

Chunk 0 of 23
Word Count: 1427
Character Count: 8974

Document Content:

Filed Pursuant to Rule 424(b)(5)

File No. 333-291822

PROSPECTUS SUPPLEMENT

(To Prospectus Dated December 9, 2025)

Synergy CHC Corp.

Common Stock

We have entered into a sales
agreement with Roth Capital Partners, LLC (the “Lead Agent”) and Bancroft Capital LLC (an “Agent” and together
with the Lead Agent the “Agents”) relating to the issuance and sale of our common stock offered by this prospectus. In accordance
with the terms of the sales agreement, we may offer and sell shares of our comment stock under this prospectus having an aggregate offering
price of up to $5.69 million from time to time through or to the Agents.

Our common stock is traded on the Nasdaq Capital Market, or Nasdaq,
under the symbol “SNYR.” On December 8, 2025, the closing sale price of our common stock on Nasdaq was $1.82 per share.

As of the date of this prospectus
supplement, the aggregate market value of our outstanding common stock held by non-affiliates is $17.1 million based on 11,251,853 shares
of outstanding common stock, of which 6,347,133 shares are held by non-affiliates, and a per share price of $2.69, which was the closing
sale price of our common stock as quoted on the Nasdaq Capital Market on October 22, 2025. Pursuant to General Instruction I.B.6 of Form
S-3, in no event will we sell shares pursuant to this prospectus with a value of more than one-third of the aggregate market value of
our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates
is less than $75,000,000. During the 12 calendar months prior to, and including, the date of this prospectus, we have not sold any securities
pursuant to General Instruction I.B.6 of Form S-3.

Sales of shares of our common
stock under this prospectus supplement, if any, may be made by any method deemed to be an “at the market offering” as defined
in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act.

The Agents are not required
to sell any specific number of shares of our common stock. The Agents have agreed to use their commercially reasonable efforts consistent
with its normal trading and sales practices, on mutually agreed terms between the Agents and us. There is no arrangement for funds to
be received in any escrow, trust or similar arrangement. The Agents will be entitled to compensation under the terms of the sales agreement
at a commission rate equal to 3.0% of the gross proceeds of the sales price of common stock that they sell. The net proceeds from any
sales under this prospectus supplement will be used as described under “Use of Proceeds.” The proceeds we receive from sales
of our common stock, if any, will depend on the number of shares actually sold and the offering price of such shares.

In connection with the sale
of common stock on our behalf, the Agents will be deemed to be underwriters within the meaning of the Securities Act, and their compensation
as Agents will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the
Agents with respect to certain liabilities, including liabilities under the Securities Act.

We are a “smaller reporting
company” as defined under the federal securities laws and, under applicable SEC rules, we have elected to comply with certain reduced
public company reporting and disclosure requirements.

Investing in our securities
is highly speculative and involves a high degree of risk. You should read carefully and consider the information contained in and incorporated
by reference under “Risk Factors” beginning on page S-8 of this prospectus supplement, and the risk factors
contained in other documents incorporated by reference.

Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement is truthful or complete. Any representation to the contrary is a criminal offense.

Roth Capital Partners	Bancroft
Capital LLC

The date of this prospectus supplement is December 9, 2025

TABLE OF CONTENTS

PROSPECTUS SUPPLEMENT

Page

About This Prospectus Supplement	S-ii

Cautionary Note Regarding Forward-Looking Statements	S-iii

Prospectus Summary	S-1

The Offering	S-7

Risk Factors	S-8

Use of Proceeds	S-9

Dilution	S-9

Description of our Common Stock	S-10

Plan of Distribution	S-13

Legal Matters	S-14

Experts	S-14

Where You Can Find More Information	S-14

Incorporation of Certain Information By Reference	S-15

PROSPECTUS

ABOUT THIS PROSPECTUS	ii

PROSPECTUS SUMMARY	1

RISK FACTORS	7

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	8

USE OF PROCEEDS	9

THE SECURITIES WE MAY OFFER	10

DESCRIPTION OF CAPITAL STOCK	11

DESCRIPTION OF DEBT SECURITIES	14

DESCRIPTION OF STOCK WARRANTS	20

DESCRIPTION OF SUBSCRIPTION RIGHTS	21

DESCRIPTION OF UNITS	22

FORMS OF SECURITIES	23

PLAN OF DISTRIBUTION	25

LEGAL MATTERS	28

EXPERTS	28

DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES	29

ADDITIONAL INFORMATION	30

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE	31

You should rely only on
the information we have provided or incorporated by reference in this prospectus supplement. We have not authorized anyone to provide
you with information different from that contained or incorporated by reference in this prospectus supplement.

This prospectus supplement
is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so.

You should assume that
the information contained in this prospectus supplement is accurate only as of their respective dates and that any information we have
incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery
of this prospective supplement for any sale of securities.

ABOUT THIS PROSPECTUS SUPPLEMENT

This prospectus supplement
is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a shelf registration
process. Under the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $100
million from time to time under this prospectus supplement at prices and on terms to be determined by market conditions at the time of
offering.

This prospectus supplement
describes the specific terms of the common stock we are offering and also adds to, and updates information contained in the documents
incorporated by reference into this prospectus supplement. To the extent there is a conflict between the information contained in this
prospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this prospectus supplement
that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this
prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later
date —for example, a document incorporated by reference into this prospectus supplement —the statement in the document having
the later date modifies or supersedes the earlier statement.

You should rely only on the
information contained in, or incorporated by reference into this prospectus supplement and in any free writing prospectus that we may
authorize for use in connection with this offering. We have not, and the sales agents have not, authorized any other person to provide
you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not,
and the sales agents are not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer
or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom
it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the documents
incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this
offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and
prospects may have changed since those dates. You should read this prospectus supplement, the documents incorporated by reference into
this prospectus supplement, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety
before making an investment decision. You should also read and consider the information in the documents to which we have referred you
in the sections of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation by Reference.”